Merck & Co. is in advanced talks to buy drugmaker Terns Pharmaceuticals Inc., according to people familiar with the matter.
Presents at TD Cowen 46th Annual Health Care Conference Transcript Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie Merck: Why Investors Should Remain Bullish Despite ...
Pharmaceutical company Merck is nearing a roughly $6 billion all-cash deal to acquire biotech firm Terns Pharma , the ...
March 24 (Reuters) - Merck is nearing a roughly $6 billion all-cash deal to buy biotech firm Terns Pharma, the ...
After generating interest from the likes of Pfizer and GSK, Quotient Therapeutics’ somatic genomics platform has attracted ...
Pharmaceutical giant Merck is reportedly closing in on a landmark acquisition of biotech company Terns Pharma in an all-cash ...
Why Merck’s new IBD genetics deal matters for MRK stock Merck (MRK) just signed a multi year research collaboration with ...
Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, today announced that it has entered a multi-year research collaboration agreement with Merck, known as ...
MRK, is presenting new long term data on its GARDASIL 9 and GARDASIL HPV vaccines at a major international HPV congress. The ...
High-sensitivity sequencing of recurrent, cell-type–specific variants aims to strengthen causal inference versus germline ...
Today's Research Daily features new research reports on 16 major stocks, including Merck Co., Inc. (MRK), TotalEnergies SE ...
Merck (MRK) stock is in focus as the FDA approves a label expansion for the company's once-yearly parasiticide treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results